Metabolic Dysfunction-Associated Liver Diseases

Questions discussed in this category

How do you incorporate other pharmacologic bariatric/appetite suppressants in the context of their clinical care plan for MASLD?

1 Answer available

How does a patient who is PNPLA-3 positive (heterozygote or homozygote) impact how you formulate their therapeutic plan?

2 Answers available

What is your approach on the pursuit of bariatric surgery in a patient with advanced fibrosis?

1 Answer available

How do you approach a patient's candidacy for simultaneous liver transplant and bariatric surgery if MASLD is the etiology of their end-stage liver disease?

1 Answer available

If you do not have easy access to shear wave elastography (aka Fibroscan), what do you recommend for non-invasive tests to determine if a MASLD patient has clinically significant portal hypertension and risk-stratify them?

1 Answer available

How does presence of clinically significant portal hypertension change patient prognosis in MASLD?

1 Answer available

Do you recommend the use of SGLT2 inhibitors to reduce the risk of liver cirrhosis in patients with Type 2 diabetes mellitus?

1 Answer available

How do you approach an obese patient on long-term methotrexate with normal liver tests in terms of workup for underlying fatty liver?

Would you start with a baseline ultrasound and then pursue further workup such as fibroscan if fatty liver is present, or other?

1 Answer available

Papers discussed in this category

International journal of molecular sciences, 2022 Mar 13

SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection.

Related Topics